Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, O' Neal J, Ritchey JK, Rettig MP, Gao F, Rettig G, Turk R, Lee BH, Cooper ML, DiPersio JF. Xiang J, et al. Among authors: o neal j. Leukemia. 2023 Dec;37(12):2448-2456. doi: 10.1038/s41375-023-02039-z. Epub 2023 Oct 5. Leukemia. 2023. PMID: 37798328 Free PMC article.
An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, Rettig MP, Wang B, Eissenberg LG, Ghobadi A, Gehrs LN, Prior JL, Achilefu S, Miller CA, Fronick CC, O'Neal J, Gao F, Weinstock DM, Gutierrez A, Fulton RS, DiPersio JF. Cooper ML, et al. Leukemia. 2018 Sep;32(9):1970-1983. doi: 10.1038/s41375-018-0065-5. Epub 2018 Feb 20. Leukemia. 2018. PMID: 29483708 Free PMC article.
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
O'Neal J, Ritchey JK, Cooper ML, Niswonger J, Sofía González L, Street E, Rettig MP, Gladney SW, Gehrs L, Abboud R, Prior JL, Haas GJ, Jayasinghe RG, Ding L, Ghobadi A, Vij R, DiPersio JF. O'Neal J, et al. Leukemia. 2022 Jun;36(6):1625-1634. doi: 10.1038/s41375-022-01559-4. Epub 2022 Apr 14. Leukemia. 2022. PMID: 35422095 Free PMC article.
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy.
Alhallak K, Sun J, Wasden K, Guenthner N, O'Neal J, Muz B, King J, Kohnen D, Vij R, Achilefu S, DiPersio JF, Azab AK. Alhallak K, et al. Leukemia. 2021 Aug;35(8):2346-2357. doi: 10.1038/s41375-021-01127-2. Epub 2021 Jan 21. Leukemia. 2021. PMID: 33479469 Free PMC article.
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.
O'Neal J, Cooper ML, Ritchey JK, Gladney S, Niswonger J, González LS, Street E, Haas GJ, Carter A, Amayta PN, Gao F, Lee BH, Choi D, Berrien-Elliott M, Zhou A, Fehniger TA, Rettig MP, DiPersio JF. O'Neal J, et al. Blood Adv. 2023 Oct 24;7(20):6009-6022. doi: 10.1182/bloodadvances.2023010032. Blood Adv. 2023. PMID: 37399471 Free PMC article.
VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.
Fontana F, Scott MJ, Allen JS, Yang X, Cui G, Pan D, Yanaba N, Fiala MA, O'Neal J, Schmieder-Atteberry AH, Ritchey J, Rettig M, Simons K, Fletcher S, Vij R, DiPersio JF, Lanza GM. Fontana F, et al. Clin Cancer Res. 2021 Apr 1;27(7):1974-1986. doi: 10.1158/1078-0432.CCR-20-2839. Epub 2020 Dec 22. Clin Cancer Res. 2021. PMID: 33355244 Free PMC article.
222 results